

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| Application of : COGAN, D.,et al U.S. Appln. No. : 10/718,380 Confirmation No. : 9526 U.S. Filing Date : 11/20/2003 Title of Invention : Cytokine Inhibitors Attny. Docket No. : 9/268 |) Art Unit: 1614) Examiner: |
|--|--|
| Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 | |
| April 7, 2004 | |
| TRANSMITTAL LETTER FOR INFORM. | ATION DISCLOSURE STATEMENT |
| Sir: | |
| Transmitted herewith concerning the subject application (Form 1449A/B) under 37 C.F.R. §§1.5 hereinbelow. | |
| 1.97(b). This Statement is being file date of a national application other than a continuous \$1.53 (d); ii) within three (3) months of the date of 37 C.F.R. §1.491 in an international application; if on the merits; or iv) before the mailing of a first C continued examination under 37 C.F.R. §1.114. | of entry of the national stage as set forth in ii) before the mailing of a first Office action |
| 1.97(c). This Statement is being file C.F.R. §1.97(b), but before the mailing date of: i) notice of allowance under 37 C.F.R. §1.311, or iii in the application. This Statement is being accommod to the statement of the statement is being accommod to the statement of the statemen |) an action that otherwise closes prosecution |
| A statement as specified in 37 C.F. | T.R. §1.97(e) [see below]; or |
| The fee set forth in 37 C.F.R. §1.17 | 7(p). |
| The Commissioner is hereby \$180.00 fee set forth in 37 C.F.R. | by authorized to charge payment of the §1.17(p) to Deposit Account No. |

| | ent as sp | This Statement is being filed after the period specified in 37 C.F.R. or before payment of the issue fee. This Statement is accompanied by a specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. |
|--------------------|--|--|
| | 1.97(e) | • |
| | stateme | Each item of information contained in the instant information disclosure ent was first cited in any communication from a foreign patent office in a part foreign application not more than three (3) months prior to the filing of ant information disclosure statement; or |
| | stateme foreign making informa §1.56(c | No item of information contained in the instant information disclosure ent was cited in a communication from a foreign patent office in a counterpart application, and, to the knowledge of the person signing this certification after a reasonable inquiry, no item of information contained in the instant ation disclosure statement was known to any individual designated in 37 C.F.R. b) more than three (3) months prior to the filing of the instant information are statement. |
| | | The fee set forth in 37 C.F.R. §1.17(p). |
| | | The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955. |
| counte in secti | rpart appoint on 1.56 | d). Each item of information contained in the accompanying information ement was cited in a communication from a foreign patent office in a plication, which communication was not received by any individual designated (c) more than thirty (30) days prior to the filing of the accompanying sclosure statement. |
| | quired u | mmissioner is hereby authorized to charge payment of any additional filing nder 37 C.F.R. §1.16 and any patent application processing fees under 37 or credit any overpayment of same, to Deposit Account No. 02-2955. |

Triplicate copies of this form are enclosed.

Patent Department

Ridgefield, CT 06877 Tel: (203) 798-4868

Boehringer Ingelheim Corp.

900 Ridgebury Road, P.O. Box 368

Respectfully submitted,

Anthony P. Bottino

Attorney for Applicant(s)

Reg. No. 41,629

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner For Patents

P. O. Box 1450

Alexandria, VA 22313-1450

on April 7, 2004.

Anthony P. Bottino, Reg. No. 41,629

PTO/SB/08a (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Application Number 10/718,380

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/718,380

Filing Date November 20, 2003

First Named Inventor Cogan, D., et al

Art Unit 1614

Examiner Name to be assigned

(Use as many sheets as necessary) Calminist Name to be a Sheet 1 of 3 Attorney Docket Number 9/268

| U. S. PATENT DOCUMENTS | | | | | | | |
|---|--------------------------|--|-----------------------------|--|---|--|--|
| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ^{2 (f known)} | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | | |
| | | ^{US-} 2001/044445 | 11/22/2001 | Bamaung, N., et al | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| *************************************** | <u> </u> | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | <u> </u> | US- | | | | | |
| | l | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | ļ | US- | | | | | |
| | · | US- | - | | | | |
| | | US- | | | | | |

| | FOREIGN PATENT DOCUMENTS | | | | | | | |
|-----------------------|--------------------------|---|--------------------------------|--|---|----------------|--|--|
| Examiner Initials* | Cite No.1 | Foreign Patent Document Country Code ³ 'Number ⁴ 'Kind Code ⁵ (# known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ | | |
| | 1 | WO 03/022820 | 03/20/2003 | Bristol-Myers Squibb | | | | |
| | † | WO 00/24735 | 05/04/2000 | Dow Agrosciences | | | | |
| ••••• | 1 | WO 03/029210 A2 | 04/10/2003 | Merck & Co. | | | | |
| •••••• | 1 | WO 96/32382 | 10/17/1996 | Sanofi | | | | |
| | †····· | WO 03/030902 A1 | 04/17/2003 | Tularik Inc. | | | | |

| Examiner | Date | |
|-----------|------------|--|
| Signature | Considered | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Instruction of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

| Substitute for form 1449A/PTO | | IS ale ledolled to le | to respond to a collection of information unless it contains a valid OMB control number Complete if Known | | | |
|-------------------------------|--|-----------------------|---|------------------------|-------------------|--|
| | Cassillate to term of the case | | Application Number | 10/718,380 | | |
| İ | INFORMATION DISC | CLOS | SURE | Filing Date | November 20, 2003 | |
| | | | First Named Inventor | Cogan, D., et al | | |
| | STATEMENT BY APPLICANT | | | Art Unit | 1614 | |
| | (Use as many sheets as ne | cessary) | | Examiner Name | To be assigned | |
| She | 2 | of | 3 | Attorney Docket Number | 9/268 | |

| Examiner | Cite | Document Number | U. S. PATENT D Publication Date | Name of Patentee or | Pages, Columns, Lines, Where |
|-------------|---------------------------------------|---|--|-----------------------------|---|
| Initials* N | No.1 | Number-Kind Code ^{2 (# known)} | MM-DD-YYYY | Applicant of Cited Document | Relevant Passages or Relevant Figures Appear |
| | 1 | US- | | | |
| | · | US- | | | |
| | | US- | | | |
| | · | US- | | | |
| | † | US- | | | |
| | † | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | · | US- | | | |
| | | US- | | | |
| | · · · · · · · · · · · · · · · · · · · | US- | | | |
| | · | US- | | | |
| | · · · · · · · · · · · · · · · · · · · | US- | | | |
| | 1 | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | ······································ | | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|---|---|---|--|--|
| Cite No.1 | Foreign Patent Document Country Code ³ Number ⁴ 'Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | Τ ⁶ , |
| | WO 03/063781 A2 | 08/07/2003 | Merck & Co. | | |
| | DE 4302051 A1 | 07/28/1994 | Dr. Karl Thomae GmbH | | <u> </u> |
| | *************************************** | | | | <u> </u> |
| | *************************************** | | | ************************************** | _ |
| | No.1 | Cite No.1 Foreign Patent Document Country Code3 Number 1 Xind Code5 (if known) WO 03/063781 A2 DE 4302051 A1 | Cite No.¹ Foreign Patent Document Publication Date MM-DD-YYYY WO 03/063781 A2 08/07/2003 DE 4302051 A1 07/28/1994 | Cite No.¹ Publication Date MM-DD-YYYY Applicant of Cited Document WO 03/063781 A2 08/07/2003 Merck & Co. DE 4302051 A1 07/28/1994 Dr. Karl Thomae GmbH | Cite No.¹ Foreign Patent Document Publication Date NM-DD-YYYY Paper of Patentee or Applicant of Cited Document Passages or Relevant Passages or Relevant Figures Appear WO 03/063781 A2 08/07/2003 Merck & Co. DE 4302051 A1 07/28/1994 Dr. Karl Thomae GmbH |

| Examiner | Date | |
|-----------|------------|--|
| Signature | Considered | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Substitute for f | Substitute for form 1449B/PTO | | | | Complete if Known |
|------------------|-----------------------------------|-------------|------|------------------------|-------------------|
| | | | | Application Number | 10/718,380 |
| INFOR | MATION DI | SCLO | SURE | Filing Date | November 20, 2003 |
| STATE | STATEMENT BY APPLICANT | | | First Named Inventor | Cogan, D., et al |
| | | | | Art Unit | 1614 |
| (| (Use as many sheets as necessary) | | | Examiner Name | To be assigned |
| Sheet | 3 | of | 3 | Attorney Docket Number | 9/268 |

| | NON PATENT LITERATURE DOCUMENTS | | | | | |
|---|---------------------------------|---|---|--|--|--|
| Examiner Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² | | | |
| | | DE 4302051: Abstract for Correspondent EP 0608858 | | | | |
| | | | | | | |
| *************************************** | | | | | | |
| | | | | | | |
| | ************** | | | | | |
| | | | | | | |
| | ************* | | | | | |
| | | | | | | |
| | **************** | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | 1 | | | |
| *************************************** | *********** | · · | *************************************** | | | |
| | | | | | | |
| | | | <u> </u> | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | - | | | |
| Examiner | | Date | | | | |
| Signature | | Considered | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.